- Home
- LOVE vs CTNM Comparison
LOVE vs CTNM Comparison
Compare LOVE & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOVE
- CTNM
- Stock Information
- Founded
- LOVE 1998
- CTNM 2009
- Country
- LOVE United States
- CTNM United States
- Employees
- LOVE N/A
- CTNM N/A
- Industry
- LOVE Other Specialty Stores
- CTNM
- Sector
- LOVE Consumer Discretionary
- CTNM
- Exchange
- LOVE Nasdaq
- CTNM Nasdaq
- Market Cap
- LOVE 280.7M
- CTNM 248.7M
- IPO Year
- LOVE 2018
- CTNM 2024
- Fundamental
- Price
- LOVE $14.20
- CTNM $12.05
- Analyst Decision
- LOVE Strong Buy
- CTNM Strong Buy
- Analyst Count
- LOVE 5
- CTNM 5
- Target Price
- LOVE $30.00
- CTNM $22.20
- AVG Volume (30 Days)
- LOVE 483.5K
- CTNM 192.3K
- Earning Date
- LOVE 09-11-2025
- CTNM 11-05-2025
- Dividend Yield
- LOVE N/A
- CTNM N/A
- EPS Growth
- LOVE 33.72
- CTNM N/A
- EPS
- LOVE 0.79
- CTNM N/A
- Revenue
- LOVE $690,298,000.00
- CTNM N/A
- Revenue This Year
- LOVE $6.80
- CTNM N/A
- Revenue Next Year
- LOVE $7.26
- CTNM N/A
- P/E Ratio
- LOVE $18.57
- CTNM N/A
- Revenue Growth
- LOVE N/A
- CTNM N/A
- 52 Week Low
- LOVE $12.12
- CTNM $3.35
- 52 Week High
- LOVE $39.49
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- LOVE 24.00
- CTNM 59.68
- Support Level
- LOVE $16.35
- CTNM $10.65
- Resistance Level
- LOVE $16.87
- CTNM $12.80
- Average True Range (ATR)
- LOVE 0.53
- CTNM 0.92
- MACD
- LOVE -0.29
- CTNM -0.09
- Stochastic Oscillator
- LOVE 0.73
- CTNM 68.90
About LOVE The Lovesac Company
The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.